TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
KFF Health News published a selection of reader letters responding to its recent reporting on health care costs and dementia care. The letters describe insurance affordability and access problems, debate the risks and uses of medication for dementia-related symptoms, and raise concerns about other aspects of care. They are readers’ experiences and views, not a representative survey or an official policy announcement.
KFF Health News published a selection of reader letters responding to recent coverage of U.S. health care costs and dementia care, including accounts of rising insurance costs, delayed access to care, and difficult decisions about medication and safety. The letters offer personal experiences and arguments about the system; they are not a survey or a new government finding.
In a letter responding to Hayat Norimine’s Sept. 22 report on rising health insurance costs, Clay Johnston of Austin, Texas, argues that the country’s medical capabilities do not guarantee that people can afford to use them. He points to the report’s accounts of a family going without insurance after premiums rose and a person who kept coverage but waited weeks to see a doctor because of a $10,000 deductible. Those examples, Johnston writes, show different ways costs can impede care.
Johnston says insurance design can discourage people from seeking early treatment, filling prescriptions or attending follow-up appointments. He calls for clinicians to have a role in shaping coverage alongside the people who design care plans, arguing that coverage and care should be designed together. That is his proposed approach, not a policy change reported by KFF Health News.
Other letters respond to Jordan Rau’s Sept. 30 reporting on sedating medications for people with dementia. Nora Staffanell of Monroe, New York, describes choosing medication and paying for one-on-one support while caring for her husband, whose agitation and violence made home care unsafe. Another letter argues that avoiding drugs should not be the only goal: it says clinicians should look for causes of distress, try person-centered, non-drug approaches where appropriate, and consider medication when symptoms are severe, dangerous or highly distressing.
Costs Can Block Early Care
The letters put a human face on two distinct pressures: the price of accessing care and the decisions families face when dementia-related behavior creates safety risks. Johnston’s examples suggest that having insurance does not necessarily mean a person can afford a visit or treatment when a high deductible applies. Staffanell’s account shows how caregiving choices can involve safety, available facilities, personal finances and a loved one’s quality of life.
The letters do not establish how common these experiences are, but they identify practical questions for patients, caregivers and policymakers. What services does a plan make affordable before a condition worsens? How should clinicians weigh medication benefits against risks for an individual with dementia? The correspondents differ in emphasis, but each points to a gap between what care may be recommended and what a patient or family can access or manage.
Popular right now
Vitamix Propel Series 750 Professional-Grade Blender, 4 Programs, Black
Apple AirPods Pro 3 Wireless Earbuds with Active Noise Cancellation
Shark PowerPro Reveal Plus Cordless Vacuum Cleaner, Charcoal, IZ376H
As an affiliate, we earn on qualifying purchases.
Reports Behind the Letters
KFF Health News describes Letters to the Editor as a periodic feature that publishes a selection of public comments. The outlet says it welcomes comments, requires full names and edits letters for length and clarity. The views in this selection belong to the writers, rather than serving as formal guidance from KFF Health News.
The letters refer to two earlier stories: Norimine’s Sept. 22 report on health insurance costs affecting health care workers, and Rau’s Sept. 30 report on medication used to sedate people with dementia. One correspondent cites American Psychiatric Association recommendations, as summarized in the supplied material, that antipsychotics outside emergencies be considered for severe, dangerous or substantially distressing agitation or psychosis after non-drug approaches have been assessed. The source also notes that the FDA approved brexpiprazole in 2023 for agitation associated with Alzheimer’s dementia. These references do not mean the treatment is appropriate for every patient.
“What good is our health system if most people cannot afford to use it?”
— Clay Johnston, Austin, Texas
Letters Are Not Population Data
The supplied material does not establish how frequently people face the insurance barriers or dementia-care circumstances described. The letters are selected submissions, not a representative measure of patients’ experiences. It also does not provide a response from insurers, clinicians or policymakers to Johnston’s call for joint coverage and care design.
Staffanell’s account is one family’s experience and cannot determine what treatment is appropriate for another person. The excerpt includes discussion of medication risks and guidance but ends before listing all risks or presenting the full letter. Details about any broader policy response or follow-up from KFF Health News are not provided.
No Policy Change Reported
The source describes a publication of reader letters, not a government decision, insurer change or clinical guideline announcement. The next developments, if any, are not specified. Readers seeking more detail can refer to the original KFF Health News reports cited in the letters and to the complete letter selection for the correspondents’ full arguments.
For families making dementia-care decisions, the letters do not replace individualized clinical guidance. Treatment choices depend on a person’s symptoms, circumstances and medical assessment; the supplied material does not offer advice for an individual case.
Key Questions
What is the news development?
KFF Health News published a selection of reader letters responding to its reporting on insurance costs and dementia care. The publication is a letters feature, not a new policy announcement.
What did the letter about insurance costs argue?
Clay Johnston argued that high premiums and deductibles can make care difficult to afford, even for people with coverage. He called for clinicians to help shape coverage alongside care design; that is his proposal, not a reported change to insurance policy.
Did the letters say dementia medications should always be avoided?
No. One correspondent emphasized the risks of using sedating drugs for convenience, while another argued that medication may be appropriate in some serious cases after clinicians assess symptoms and non-drug approaches. The letters do not offer an individual treatment recommendation.
Do these letters show how common the problems are?
No. The letters are selected reader submissions and are not a representative survey or a population-level study. They describe correspondents’ experiences and views.
Source: rss
